The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 in Asian Patients with Advanced Solid Malignancies and Asian Patients with Child-Pugh A to B7 Advanced Hepatocellular Carcinoma (HCC) in the escalation phase, EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer and solid tumour with biopsy available in the expansion phase.
- collapse Metabolic changes in prostate cancer patients with Androgen-ablation therapy (AAT)
- collapse An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer
- collapse A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients with Metastatic Castration-Resistant Prostate Cancer.
- collapse A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status.
- collapse A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status (SAGE)
- collapse A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study of AZD8931 In Combination with Anastrozole in Post menopausal Women With Hormone Receptor positive, Endocrine Therapy naive, Locally advanced or Metastatic Breast Cancer (MINT)
- collapse A Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN® treatment under condition of actual usage in clinical practice
- collapse A Phase I, Single-center, Randomized, Open-label, Crossover Study to Compare the White (Current Phase II) and Blue (Planned Phase III) Capsule Formulations of AZD6244 Hyd-Sulfate in Healthy Male Subjects.
- collapse A non-interventional survey on the EGFR mutation status in completely resected Chinese NSCLC patients with adenocarcinoma histology
